Lukito Gozali - PT Kalbe Head Relations
| PTKFF Stock | USD 0.1 0.00 0.00% |
Executive
Lukito Gozali is Head Relations of PT Kalbe Farma
| Age | 44 |
| Phone | 62 21 4287 3888 |
| Web | https://www.kalbe.co.id |
PT Kalbe Management Efficiency
The company has return on total asset (ROA) of 0.106 % which means that it generated a profit of $0.106 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1673 %, meaning that it generated $0.1673 on every $100 dollars invested by stockholders. PT Kalbe's management efficiency ratios could be used to measure how well PT Kalbe manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Linda MD | Novartis AG ADR | 61 | |
| Kimberly Jablonski | Bristol Myers Squibb | N/A | |
| Jacquie CFA | Gilead Sciences | N/A | |
| Robert Weltevreden | Novartis AG ADR | 52 | |
| Flavius MD | Gilead Sciences | N/A | |
| Vasant Narasimhan | Novartis AG ADR | 48 | |
| Vasant MD | Novartis AG ADR | 48 | |
| Deborah JD | Gilead Sciences | 59 | |
| Adrian Kemp | AstraZeneca PLC ADR | N/A | |
| Sandra Esq | Bristol Myers Squibb | 63 | |
| Steffen Lang | Novartis AG ADR | 57 | |
| Susan MD | AstraZeneca PLC ADR | 58 | |
| Joseph Eiden | Bristol Myers Squibb | 75 | |
| Aharon Gal | Novartis AG ADR | N/A | |
| Klaus Moosmayer | Novartis AG ADR | 56 | |
| Andrew Barnett | AstraZeneca PLC ADR | N/A | |
| Pierre Chancel | Sanofi ADR | 67 | |
| Steven Baert | Novartis AG ADR | 45 | |
| Linda Higgins | Gilead Sciences | 62 | |
| Deborah Telman | Gilead Sciences | 59 | |
| Catherine Owen | Bristol Myers Squibb | 54 | |
Management Performance
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 |
PT Kalbe Farma Leadership Team
Elected by the shareholders, the PT Kalbe's board of directors comprises two types of representatives: PT Kalbe inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PTKFF. The board's role is to monitor PT Kalbe's management team and ensure that shareholders' interests are well served. PT Kalbe's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PT Kalbe's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lanny Soputro, G HR | ||
| Kurniawan Suhartono, Head Unit | ||
| Bapak Vidjongtius, Corporate Secretary, Independent Director, Chairman of Good Corporate Governance Committee and Member of Bus. Risk Committee | ||
| Sie Djohan, Management Devel | ||
| Lukito Gozali, Head Relations |
PTKFF Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PT Kalbe a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.12 % | |||
| Current Valuation | 6.11 B | |||
| Shares Outstanding | 46.26 B | |||
| Shares Owned By Insiders | 58.08 % | |||
| Shares Owned By Institutions | 15.23 % | |||
| Price To Book | 5.15 X | |||
| Price To Sales | 3.56 X | |||
| Revenue | 26.26 T |
Currently Active Assets on Macroaxis
Other Information on Investing in PTKFF Pink Sheet
PT Kalbe financial ratios help investors to determine whether PTKFF Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PTKFF with respect to the benefits of owning PT Kalbe security.